EHA 2019: Three-year data from the DALIAH trial: Recombinant interferon alpha-2 VS hydroxyurea in patients with myeloproliferative neoplasms

Trine Alma Knudsen | EHA 2019 | Juni 17, 2019

Speaker: Trine Alma Knudsen

The DALIAH trial is an ongoing investigator initiated Danish multicenter randomized controlled phase III clinical trial. This study shows, that at 36 months the clinicohematologicalORR was higher in patients withessential thrombocythemia, polycythemia veraand prefibroticmyelofibrosistreatedwith hydroxyurea. Click and hear Trine Alma Knudsen explain the new data.